TZ-101 Platform
Cell Therapy Enhancement (Oncology, Autoimmune, Neurodegenerative)
Pre-clinicalActive
Key Facts
Indication
Cell Therapy Enhancement (Oncology, Autoimmune, Neurodegenerative)
Phase
Pre-clinical
Status
Active
Company
About Targazyme
Targazyme is pioneering a novel approach to cell and gene therapy by focusing on improving the delivery and engraftment of therapeutic cells. Its lead technology, TZ-101, acts as a 'GPS' for cells, aiming to multiply their effective delivery to disease sites by 400-1200%. The company has secured significant funding, built a strong IP portfolio, and assembled a seasoned leadership and advisory team to advance its platform towards clinical validation.
View full company profile